Evidence for cyclic diguanylate as a vaccine adjuvant with novel immunostimulatory activities.

[1]  Yoshihiro Hayakawa,et al.  STING is a direct innate immune sensor of cyclic-di-GMP , 2011, Nature.

[2]  R. Cox,et al.  Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice. , 2011, Vaccine.

[3]  E. Montomoli,et al.  Current adjuvants and new perspectives in vaccine formulation , 2011, Expert review of vaccines.

[4]  V. Schijns,et al.  Trends in vaccine adjuvants , 2011, Expert review of vaccines.

[5]  N. Garçon,et al.  Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems , 2011, Expert review of vaccines.

[6]  H. Sahly.  MF59™ as a vaccine adjuvant: a review of safety and immunogenicity , 2010 .

[7]  H. Qiu,et al.  3',5'-Cyclic diguanylic acid elicits mucosal immunity against bacterial infection. , 2009, Biochemical and biophysical research communications.

[8]  K. Ishii,et al.  A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP , 2009, The Journal of experimental medicine.

[9]  Yifan Ma,et al.  Toll-Like Receptor 3 Ligand and Retinoic Acid Enhance Germinal Center Formation and Increase the Tetanus Toxoid Vaccine Response , 2009, Clinical and Vaccine Immunology.

[10]  D. Kaufman,et al.  Translational Mini‐Review Series on Vaccines for HIV: T lymphocyte trafficking and vaccine‐elicited mucosal immunity , 2009, Clinical and experimental immunology.

[11]  D. Karaolis,et al.  c-di-GMP as a vaccine adjuvant enhances protection against systemic methicillin-resistant Staphylococcus aureus (MRSA) infection. , 2009, Vaccine.

[12]  Barbara Rehermann,et al.  Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. , 2009, The Journal of clinical investigation.

[13]  D. Zaller,et al.  Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses , 2009, BMC Immunology.

[14]  P. Marrack,et al.  Towards an understanding of the adjuvant action of aluminium , 2009, Nature Reviews Immunology.

[15]  Xiaoyu Hu,et al.  Regulation of interferon and Toll‐like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms , 2008, Immunological reviews.

[16]  J. McCullers,et al.  c-di-GMP is an effective immunomodulator and vaccine adjuvant against pneumococcal infection. , 2008, Vaccine.

[17]  S. Plotkin,et al.  Vaccines: correlates of vaccine-induced immunity. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  Henk C. Hoogsteden,et al.  Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells , 2008, The Journal of experimental medicine.

[19]  A. Camilli,et al.  Roles of cyclic diguanylate in the regulation of bacterial pathogenesis. , 2007, Annual review of microbiology.

[20]  T. Standiford,et al.  Cyclic Di-GMP Stimulates Protective Innate Immunity in Bacterial Pneumonia , 2007, Infection and Immunity.

[21]  A. Jegerlehner,et al.  TLR9 Signaling in B Cells Determines Class Switch Recombination to IgG2a , 2007, The Journal of Immunology.

[22]  J. Schroeder,et al.  Bacterial c-di-GMP Is an Immunostimulatory Molecule1 , 2007, The Journal of Immunology.

[23]  T. Ebensen,et al.  The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties. , 2007, Vaccine.

[24]  P. Sly,et al.  CpG methylation patterns in the IFNγ promoter in naive T cells: Variations during Th1 and Th2 differentiation and between atopics and non‐atopics , 2006, Pediatric Allergy and Immunology.

[25]  A. Krieg,et al.  Therapeutic potential of Toll-like receptor 9 activation , 2006, Nature Reviews Drug Discovery.

[26]  J. J. Zhang,et al.  Stat1-Dependent Synergistic Activation of T-bet for IgG2a Production during Early Stage of B Cell Activation1 , 2005, The Journal of Immunology.

[27]  S. Holland,et al.  Defects in the interferon‐γ and interleukin‐12 pathways , 2005, Immunological reviews.

[28]  Roger A. Jones,et al.  c-di-GMP displays a monovalent metal ion-dependent polymorphism. , 2004, Journal of the American Chemical Society.

[29]  N. Petrovsky,et al.  Vaccine adjuvants: Current state and future trends , 2004, Immunology and cell biology.

[30]  C. Walker,et al.  Cell-mediated immunity and the outcome of hepatitis C virus infection. , 2004, Annual review of microbiology.

[31]  P. Sly,et al.  Functional Maturation of CD4+CD25+CTLA4+CD45RA+ T Regulatory Cells in Human Neonatal T Cell Responses to Environmental Antigens/Allergens1 , 2004, The Journal of Immunology.

[32]  C. Van Lint,et al.  A Defect in Nucleosome Remodeling Prevents IL-12(p35) Gene Transcription in Neonatal Dendritic Cells , 2004, The Journal of experimental medicine.

[33]  Qing He,et al.  Antibody regulation of T-cell immunity: implications for vaccine strategies against intracellular pathogens , 2004, Expert review of vaccines.

[34]  Sambasiva P Rao,et al.  Cutting Edge: Germinal Centers Formed in the Absence of B Cell-Activating Factor Belonging to the TNF Family Exhibit Impaired Maturation and Function , 2003, The Journal of Immunology.

[35]  C. Bode,et al.  CpG DNA as a vaccine adjuvant , 2003, Expert review of vaccines.

[36]  F. Eko,et al.  Contemporary approaches to designing and evaluating vaccines against Chlamydia , 2003, Expert review of vaccines.

[37]  M. Starnbach,et al.  T cell responses to Chlamydia trachomatis. , 2002, Current opinion in microbiology.

[38]  J. Vekemans,et al.  Deficient IL-12(p35) Gene Expression by Dendritic Cells Derived from Neonatal Monocytes1 , 2001, The Journal of Immunology.

[39]  S. Dorman,et al.  Interferon-γ and interleukin-12 pathway defects and human disease , 2000 .

[40]  T. Manser,et al.  Amplified follicular immune complex deposition in mice lacking the Fc receptor gamma-chain does not alter maturation of the B cell response. , 1997, Journal of immunology.

[41]  P. Matzinger,et al.  Neonatal Tolerance Revisited: Turning on Newborn T Cells with Dendritic Cells , 1996, Science.

[42]  J. H. Boom,et al.  Regulation of cellulose synthesis in Acetobacter xylinum by cyclic diguanylic acid , 1987, Nature.

[43]  M. Struthers,et al.  Synthesis and immunological activities of novel agonists of toll-like receptor 9. , 2010, Cellular immunology.

[44]  R. Coffman,et al.  Interleukin-10 and the interleukin-10 receptor. , 2001, Annual review of immunology.